Full Press Release Details
BioScience to Report Fiscal Fourth Quarter 2018 Results and Business Update
Live Conference Call and Webcast
Scheduled for September 6, 2018, at 4:30 p.m. ET
ENGLEWOOD, CO / ACCESSWIRE / August
30, 2018 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on global commercialization of
novel products addressing significant medical needs, today announced that the company will present its operational results for
the fiscal fourth quarter 2018 on Thursday, September 6, 2018, at 4:30 p.m. ET. The company will review recent accomplishments
and provide an overview of its business and growth strategy.
Conference Call Information:
Interested participants and investors
may access the conference call by dialing either:
1 (877) 407-9124 (toll-free)
1 (201) 689-8584 (international)
The webcast will be accessible live
and archived on Aytu BioScience's website, within the Investors section under Corporate Presentations & Media, at aytubio.com,
A replay of the call will be available
for fourteen days. Access the replay by calling 1 (877) 481-4010 (toll-free) or 1 (919) 882-2331 (international) and using the
replay access code 37418.
About Aytu BioScience, Inc.
Aytu BioScience is a commercial-stage
specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs. The
company currently markets Natesto , the only FDA-approved nasal formulation of testosterone for men with hypogonadism (low
testosterone, or "Low T"). Additionally, Aytu is developing MiOXSYS , a novel, rapid semen analysis system with
the potential to become a standard of care for the diagnosis and management of male infertility caused by oxidative stress. MiOXSYS
is commercialized outside of the U.S. where it is a CE Marked, Health Canada cleared, Australian TGA approved, Mexican COFEPRAS
approved product, and Aytu is planning U.S.-based clinical trials in pursuit of 510k de novo medical device clearance by the FDA.
Aytu recently acquired exclusive U.S. and Canadian rights to ZolpiMist , an FDA-approved, commercial-stage prescription
sleep aid indicated for the short-term treatment of insomnia characterized by difficulties with sleep initiation. Aytu's strategy
is to continue building its portfolio of revenue-generating products, leveraging its focused commercial team and expertise to
build leading brands within large, growing markets. For more information visit aytubio.com.
Forward-Looking Statements
This press release includes forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange
Act of 1934, or the Exchange Act. All statements other than statements of historical facts contained in this presentation, are
forward-looking statements. Forward looking statements are generally written in the future tense and/or are preceded by words
such as ' may,'' ' will,'' ''should,'' ' forecast,'' ' could,'' ' expect,'' ''suggest,'' ' believe,'' ' estimate,'' ' continue,''
' anticipate,'' ' intend,'' ' plan,'' or similar words, or the negatives of such terms or other variations on such terms or comparable
terminology. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events
or results to differ materially. These risks and uncertainties include, among others: the risks related to not being able to present
operational results for the fiscal fourth quarter and full year 2018 on Thursday, September 6, 2018, at 4:30 p.m. ET, risks relating
to gaining market acceptance of our products, obtaining reimbursement by third-party payors, the potential future commercialization
of our product candidates, the anticipated start dates, durations and completion dates, as well as the potential future results,
of our ongoing and future clinical trials, the anticipated designs of our future clinical trials, anticipated future regulatory
submissions and events, our anticipated future cash position and future events under our current and potential future collaboration.
We also refer you to the risks described in ' Risk Factors'' in Part I, Item 1A of Aytu BioScience, Inc.'s Annual Report on Form
10-K and in the other reports and documents we file with the Securities and Exchange Commission from time to time.
Contact for Investors:
SOURCE: Aytu BioScience,